A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 363-368

  Hirai, F ^a   Yamanaka, T ^b   Taguchi, K ^a   Daga, H ^c   Ono, A ^d   Tanaka, K ^e   Kogure, Y ^f   Shimizu, J ^g   Kimura, T ^h   Fukuoka, J ⁱ   Iwamoto, Y ^j   Sasaki, H ^k   Takeda, K ^c   Seto, Takashi ^a   Ichinose, Y ^a   Nakagawa, K ^e   Nakanishi, Y ^l  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^j HIROSHIMA CITY HOSPITAL   (Japan)

^k NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^l KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Advanced thymic carcinoma; Carboplatin; Paclitaxel; The standard treatments for non small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; THYMIC CARCINOMA; THYMUS CANCER; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; THYMOMA; THYMUS NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; THYMOMA; THYMUS NEOPLASMS;

EID: 84925300119     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu541     Document Type: Article

References (23)

1. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003; 105: 546-551.
2. de Jong WK, Blaauwgeers JL, Schaapveld M et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44: 123-130.
3. Liu HC, Hsu WH, Chen YJ et al. Primary thymic carcinoma. Ann Thorac Surg 2002; 73: 1076-1081.
4. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003; 76: 878-884; discussion 884-875.
5. Travis W, Brambilla E, Muller-Hermelink H, Harris C. Tumours of the Lung, Pleura, Thymus and Heart. Pathology and Genetics. Lyon: World Health Organization Classification of Tumours, IARC Press 2004.
6. Berruti A, Borasio P, Gerbino A et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999; 81: 841-845.
7. Koizumi T, Takabayashi Y, Yamagishi S et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002; 25: 266-268.
8. Loehrer PJ, Sr, Jiroutek M, Aisner S et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001; 91: 2010-2015.
9. Grassin F, Paleiron N, Andre M et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol 2010; 5: 893-897.
10. Yoh K, Goto K, Ishii G et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003; 98: 926-931.
11. Loehrer PJ, Sr, Kim K, Aisner SC et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994; 12: 1164-1168.
12. Agatsuma T, Koizumi T, Kanda S et al. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 2011; 6: 2130-2134.
13. Fornasiero A, Daniele O, Ghiotto C et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991; 68: 30-33.
14. Igawa S, Murakami H, Takahashi T et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010; 67: 194-197.
15. Furugen M, Sekine I, Tsuta K et al. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn J Clin Oncol 2011; 41: 1013-1016.
16. Lemma GL, Lee JW, Aisner SC et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011; 29: 2060-2065.
17. Okuma Y, Hosomi Y, Takagi Y et al. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer 2011; 74: 492-496.
18. Palmieri G, Merola G, Federico P et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 2010; 21: 1168-1172.
19. Oshita F, Kasai T, Kurata T et al. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results. Jpn J Clin Oncol 1995; 25: 208-212.
20. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
21. Ohe Y, Ohashi Y, Kubota K et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18: 317-323.
22. Maruyama R, Suemitsu R, Okamoto T et al. Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients. Oncology 2006; 70: 325-329.
23. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485-2492.